CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
sunitinibdrug
Likely dose
sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00616109
NCT00616109Phase 2Completed
CompareCT.gov

Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

University of Michigan Rogel Cancer Center·interventional·Posted Feb 15, 2008·Updated Apr 21, 2014

In Brief

A Phase 2 clinical trial evaluating sunitinib for Extensive-Stage Small Cell Lung Cancer. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The goal of this study is to determine the progression-free survival rate in patients with extensive-stage small cell lung cancer who had achieved complete response, partial response, or stable disease with their previous platinum chemotherapy regimen, such as cisplatin or carboplatin in combination with etoposide or irinotecan. In addition, the safety and effectiveness of sunitinib will also be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-Stage Small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 15, 2008
Enrollment StartSep 1, 2007
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.4 years ago

Interventions

sunitinibdrug

Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.